Aurobindo nabs bankrupt Natrol for $132.5M; Scots reject Roche's Perjeta as too costly;

@FiercePharma: Top-read in #pharma #manufacturing Tues: Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. More | Follow @FiercePharma

@EricPFierce: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More | Follow @EricPFierce

@CarlyHFierce: Mylan visits Disney Parks for a little EpiPen marketing magic. More | Follow @CarlyHFierce

> India's Aurobindo Pharma won a bankruptcy auction to buy the California-based nutritional supplements company Natrol for $132.5 million. Report

> After Scotland's cost-effectiveness watchdogs refused to approve Roche's ($RHHBY) new breast cancer drug Perjeta, patient groups started agitating for a price cut. Report

> Pfizer ($PFE) launched an authorization system for its products in Malaysia, to help patients separate authentic products from counterfeits. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: With fresh infusion of cash in tow, Thync rolls out wearable, noninvasive device to elevate mood. Article | Follow @FierceMedDev

@VarunSaxena2: Aethlon to begin U.S. testing for its Ebola treatment device by year end. More | Follow @VarunSaxena2

@EmilyWFierce: Mark your calendars: EU Commission will decide by Nov. 28 whether or not to approve $MDT's $43B deal for $COV. More  | Follow @EmilyWFierce

> Medtronic borrows $16B to cover rising costs of Covidien deal. Article

> FDA clears first patient-specific spinal rod. More

Biotech News

@FierceBiotech: $AMGN and $AZN psoriasis drug beats blockbuster Stelara ($JNJ) in head-to-head trial. Report | Follow @FierceBiotech

@JohnCFierce: Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/device. News | Follow @JohnCFierce

@DamianFierce: Hep C market share optimism has $ABBV up. Also, cab ads. Picture | Follow @DamianFierce

> Takeda's Millennium re-ups with Presage on cancer drug combo effort. Item

> Blueprint Medicines banks $50M for its personalized take on cancer. News

> Fujifilm says its flu drug is an Ebola solution in waiting. Article

Drug Delivery News

> Drug-loaded milk could offer oral HIV/AIDS prevention to children. Story

> Alnylam adds two RNAi programs to its hepatitis pipeline. Article

> Arrowhead's midstage hep B data shows promise for RNA-based 'functional cure.' News

> FDA clears syringe that prevents needlestick injuries. News

> Nasal spray for migraines under development. Story

Diagnostics News

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Story

> Quest CEO says 'no' to CRO. Report

> Study: Myriad skin cancer Dx shows reduction in indeterminate diagnoses. More

> GE Healthcare lends imaging tech to Takeda for Dx partnership. Item

> Scientists developing machine-based algorithm for heart failure and emphysema Dx. Article

Pharma Marketing News

> Under siege by Biogen's new long-acting Eloctate, Baxter's Advate stands its ground. Report

> Missing the old pharma swag? Take a trip down memory lane. Article

> Will GLP market growth save Novo's Victoza from Lilly's new Trulicity? More

> Contrave demand swamps Takeda's direct-delivery discount program. Story

> Mylan visits Disney Parks for a little EpiPen marketing magic. Article

And Finally... Former Apple ($AAPL) CEO John Sculley grabbed a stake in the telemedicine company MDLive, saying he sees online services "going mainstream" in coming years. Report

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.